In Vitro and In Vivo Co-delivery of siRNA and Doxorubicin by Folate-PEG-Appended Dendrimer/Glucuronylglucosyl-β-Cyclodextrin Conjugate
- 31 Downloads
We have previously reported the utility of folate-polyethylene glycol-appended dendrimer conjugate with glucuronylglucosyl-β-cyclodextrin (Fol-PEG-GUG-β-CDE) (generation 3) as a tumor-selective carrier for siRNA against polo-like kinase 1 (siPLK1) in vitro. In the present study, we evaluated the potential of Fol-PEG-GUG-β-CDE as a carrier for the low-molecular antitumor drug doxorubicin (DOX). Further, to fabricate advanced antitumor agents, we have prepared a ternary complex of Fol-PEG-GUG-β-CDE/DOX/siPLK1 and evaluated its antitumor activity both in vitro and in vivo. Fol-PEG-GUG-β-CDE released DOX in an acidic pH and enhanced the cellular accumulation and cytotoxic activity of DOX in folate receptor-α (FR-α)-overexpressing KB cells. Importantly, the Fol-PEG-GUG-β-CDE/DOX/siPLK1 ternary complex exhibited higher cytotoxic activity than a binary complex of Fol-PEG-GUG-β-CDE with DOX or siPLK1 in KB cells. In addition, the cytotoxic activity of the ternary complex was reduced by the addition of folic acid, a competitor against FR-α. Furthermore, the ternary complex showed a significant antitumor activity after intravenous administration to the tumor-bearing mice. These results suggest that Fol-PEG-GUG-β-CDE has the potential of a tumor-selective co-delivery carrier for DOX and siPLK1.
KEY WORDSPAMAM dendrimer doxorubicin siRNA folate tumor-selective drug delivery
The authors thank Ensuiko Sugar Refining for donating GUG-β-CyD.
AFAM, TH, KM, AO, RO, and HA had participated in the research design. AFAM and AO had conducted the experiments. AFAM, TH, KM, AO, and RO had performed the data analysis. AFAM and TH had drafted or contributed to the writing of the manuscript. TH, KM, KAK, HAS, AKH and HA had supervised the experiments.
Compliance with Ethical Standards
All animal procedures were carried out in accordance with the approved guidelines and with the approval of the Ethics Committee for Animal Care and Use of Kumamoto University (approval no.: C29-162).
Conflict of Interest
The authors declare that they have no conflict of interest.
- 1.American cancer society, https://www.cancer.org/research/cancer-facts-statistics/global.html.
- 24.Yamanoi T, Yoshida N, Oda Y, Akaike E, Tsutsumida M, Kobayashi N, et al. Synthesis of mono-glucose-branched cyclodextrins with a high inclusion ability for doxorubicin and their efficient glycosylation using Mucor hiemalis endo-β-N-acetylglucosaminidase. Bioorg Med Chem Lett. 2005;15(4):1009–13.CrossRefGoogle Scholar